Skip to main content

Table 2 Potential cancer markers for endometrial hyperplasia and carcinoma reported in previous literatures.

From: Altered protein expression in serum from endometrial hyperplasia and carcinoma patients

Protein Name

Endometrial Carcinoma

Endometrial Hyperplasia

 

Tissue

Serum/Plasma

Tissue

Serum/Plasma

alpha-1-antitrypsin

 

-[6]

  

alpha-1-antitrypsin precursor

-[4]

   

alpha-1-beta glycoprotein

 

+[6]

  

alpha-enolase

  

+[12]

 

antithrombin III

 

+[6]*

  

apolipoprotein A-IV

 

-[16]*

  

calcyphosine

+[14]

   

calgizzarin

+[4]

   

calgranulin A

+[11]

   

cAMP dependent protein kinase type I-beta regulatory chain

+[12]

   

chaperonin 10

+[4,7,11]

   

cleaved high molecular weight kininogen

 

-[4,6]

  

clusterin

 

+[6]

  

complement component 3

 

+[16]

  

complement component 4A

 

+[16]

  

complement component 4B

 

+[16]

  

creatine kinase B

-[4]

   

cyclophilin A

+[14,17]

  

epidermal fatty acid binding protein

+[14]

   

GAPDH

+[12]

   

heat shock 27 kDa protein

+[12]

   

heat shock 70 kDa protein 1

+[12]

 

+[12]

 

heat shock cognate 71 kDa protein

+[12]

 

+[12]

 

heterogeneous nuclear ribonucleoprotein D0

+[4]

   

heterogeneous nuclear ribonucleoproteins A2/B1

+[12]

   

inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP)

 

+[6,16,21]#

  

leucine-rich glycoprotein

 

+[6]

  

macrophage migratory inhibitory factor

+[4]

   

phosphoglycerate kinase

+[12]

 

+[12]

 

polymeric immunoglobulin receptor precursor

+[4]

   

prohibitin

+[12]

   

prolactin

 

+[15]

  

pyruvate kinase M1 or M2 isozyme

+[4]

   

serotransferrin precursor

+[12]

   

serum albumin precursor

+[12]

 

+[12]

 

serum amyloid A

 

+[15]*

  

transgelin

-[4]

   

trypomyosin fibroblast isoform TM3

+[12]

   

vimentin

  

+[12]

 
  1. References are indicated in brackets;
  2. "+", up-regulation;
  3. "-", down-regulation;
  4. "*", consistent result in this study when compared with previous studies;
  5. "#", contradictory result in this study when compared with previous studies.